Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)

Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)

Abstract Background Few prospective studies have compared the cardiovascular benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase 4 (DPP-4) inhibitors. We aimed to clarify the efficacy of dapagliflozin versus sitagliptin for modulating cardiometabolic risk factors i...

Full description

Bibliographic Details
Main Authors: Ayako Fuchigami, Fumika Shigiyama, Toru Kitazawa, Yosuke Okada, Takamasa Ichijo, Mariko Higa, Toru Hiyoshi, Ikuo Inoue, Kaoru Iso, Hidenori Yoshii, Takahisa Hirose, Naoki Kumashiro
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Cardiovascular Diabetology
Subjects:
Type 2 diabetes
Cardiometabolic risk factors
Dapagliflozin
Sitagliptin
Glycemic control
Weight loss
Online Access:https://doi.org/10.1186/s12933-019-0977-z

Internet

https://doi.org/10.1186/s12933-019-0977-z

Similar Items